Background: Pediatric gastroenteropancreatic neuroendocrine tumors are exceedingly rare. resulting in most pediatric treatment recommendations being based on data derived from adults. Trametinib is a kinase inhibitor that targets MEK1/2 and has been employed in the treatment of cancers harboring mutations in the Ras pathway. Methods: We utilized an established human pediatric gastroen... https://www.eleanorscholz.com/product-category/industrialrestaurant-business-5/